Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028925 | BIONPHARMA INC | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 11 months from now) | |
US10022344 | BIONPHARMA INC | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 11 months from now) | |
US11090280 | BIONPHARMA INC | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 11 months from now) | |
US9693979 | BIONPHARMA INC | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 11 months from now) | |
US9693978 | BIONPHARMA INC | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(1 year, 11 months from now) |
Naproxen Sodium is owned by Bionpharma Inc.
Naproxen Sodium contains Naproxen Sodium.
Naproxen Sodium has a total of 5 drug patents out of which 0 drug patents have expired.
Naproxen Sodium was authorised for market use on 17 February, 2006.
Naproxen Sodium is available in capsule;oral dosage forms.
Naproxen Sodium can be used as temporary relief of minor aches and pains; temporary reduction of fever.
The generics of Naproxen Sodium are possible to be released after 03 March, 2026.
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary relief of minor aches and pains; Temporary reduction of fever
Dosage: CAPSULE;ORAL